Clinical Trial

Frailty Assessments for Risk Assessment in Gynecologic Oncology Patients

Study acronym: FARGO
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated April 16, 2025 (before its estimated May 2025 completion). Its status may not reflect the trial's current state.
Summary
FARGO is a prospective cohort study that aims to determine the performance of preoperative frailty assessment based on the Frailty Phenotype (FP), compared to a perioperative cardiovascular risk assessment based on the combination of preoperative Revised Cardiac Risk Index (RCRI), age and occurrence of myocardial injury after noncardiac surgery (MINS), in predicting the composite of all-cause death or new disability at 6 months after surgery in patients aged 55 or older. Patients will have confirmed or suspected gynecologic cancer, undergoing cytoreductive or high-risk surgery with or without chemotherapy.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-02-10; most recent amendment 2025-04-12.
Status change: Not Yet Recruiting → Recruiting 2023-06-19
Trial Details
NCT Number NCT05738252
Lead Sponsor Population Health Research Institute
Conditions Gynecologic Cancer, Frailty, Oncology
Enrollment 280 participants
Start Date 2023-06-15
Primary Completion 2025-05 (estimated)
Study Completion 2025-10 (estimated)
Updated on ClinicalTrials.gov 2025-04-16